Hasanzadeh Haghighi Faria, Aryan Ehsan, Gholoobi Aida, Zare Hosna, Meshkat Zahra
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Rep Biochem Mol Biol. 2019 Apr;8(1):32-35.
Tuberculosis (TB) is the leading cause of death by infectious diseases worldwide, and especially prevalent in developing countries. Several vaccines against TB have been developed, recently. The aim of the present study was to design and construct a cloning vector encoding gene.
DNA was extracted from MTB H37Rv strain. Gene-specific primers were designed using Gene Runner software and the gene was amplified by PCR. The amplified fragment and pcDNA3.1(+) cloning vector were both digested with restriction enzymes, the fragment was ligated into the vector, and the TOP10 strain were transformed by the recombinant plasmid. Positive clones were identified by colony PCR, restriction enzyme digestion, and DNA sequencing.
The gene was successfully cloned into pcDNA3.1(+). A 6400 bp band for the pcDNA3.1(+)/ recombinant plasmid and a 926 bp band for were observed by colony PCR, and restriction enzyme digestion on agarose gels. The DNA sequence was 100% homologous with the fragment of H37Rv in GenBank.
In the current study, the gene of MTB was correctly cloned into pcDNA3.1(+). The expression of this recombinant vector can be studied in eukaryotic cells. Moreover, it is possible to determine the efficacy of this vector as a DNA vaccine candidate, and to test its protective function compared to BCG in animal models in future.
结核病是全球传染病致死的主要原因,在发展中国家尤为普遍。近年来已研发出几种抗结核疫苗。本研究的目的是设计并构建一种编码基因的克隆载体。
从结核分枝杆菌H37Rv菌株中提取DNA。使用Gene Runner软件设计基因特异性引物,通过PCR扩增该基因。扩增片段和pcDNA3.1(+)克隆载体均用限制性内切酶消化,将该片段连接到载体中,并用重组质粒转化TOP10菌株。通过菌落PCR、限制性内切酶消化和DNA测序鉴定阳性克隆。
该基因成功克隆到pcDNA3.1(+)中。通过菌落PCR和琼脂糖凝胶上的限制性内切酶消化,观察到pcDNA3.1(+)/重组质粒的6400 bp条带和该基因的926 bp条带。DNA序列与GenBank中H37Rv的该片段100%同源。
在本研究中,结核分枝杆菌的该基因正确克隆到pcDNA3.1(+)中。可在真核细胞中研究该重组载体的表达。此外,未来有可能确定该载体作为DNA疫苗候选物的功效,并在动物模型中测试其与卡介苗相比的保护功能。